01 / LAW
Scheduling
Check whether a state separately schedules ibogaine or noribogaine, adopts federal schedules by reference, or publishes agency guidance.
U.S. jurisdiction monitor
State Policy Map
A concise reference for tracking state laws, administrative rules, research activity, enforcement signals, and access claims related to ibogaine and noribogaine in the United States.
Policy status is not a finding of safety, availability, or legality for any individual circumstance. This page is informational and does not provide legal advice.
Reference frame
Read the status before the claim
State policy sits beneath federal drug control and above a changing mix of local enforcement, research administration, and public claims. The broader ibogaine policy and research tracker is useful for comparing these layers without treating a state-level signal as approval.
02 / RESEARCH
Public action
Distinguish an appropriation, pilot discussion, or university study from an authorized treatment pathway.
03 / ENFORCEMENT
Practice signals
Look for documented licensing, consumer-protection, controlled-substance, or professional-practice actions.
04 / ACCESS
Legal triggers
Separate Right to Try language, investigational pathways, and cross-border travel from ordinary clinical availability.
Baseline
Federal scheduling remains the starting point
Controlled status
Research activity
Enforcement record
Access claims
Ibogaine is listed in Schedule I under federal law. The DEA controlled substances list is a practical primary reference for that federal baseline; states may mirror, incorporate, or administer controlled-substance categories differently.
Noribogaine references require the same care. A research or policy discussion of a metabolite does not itself establish a state authorization, a prescribing route, or an approved treatment program. The federal status monitor helps keep federal scheduling, drug-development rules, and state developments in separate view.
Statute
Agency rule
Program record
Enforcement file
State review workflow
Four records to review in each jurisdiction
A reliable state entry does not treat policy language as a substitute for evidence. It records what a source actually establishes and notes where the public record is incomplete.
1 Statutes and rules
Confirm the controlled-substance text, incorporated schedules, and any named ibogaine or noribogaine provisions. The federal scheduling framework in 21 U.S.C. § 812 provides context, but it does not replace a state code or rule.
2 Research programs
Record enacted appropriations, agency requests, pilot mandates, and identifiable research protocols separately. The clinical evidence map helps distinguish research signals from claims that treatment is established.
3 Enforcement actions
Identify the agency, conduct alleged, legal authority cited, and procedural stage. An investigation or complaint should not be written as a final finding, and a single action should not be generalized to an entire state.
4 Unique legal triggers
Right to Try statutes and investigational-use arguments need narrow reading. The FDA’s explanation of federal Right to Try is clear that the law concerns eligible investigational drugs, not a general exception to controlled-substance law.
Access context
Cross-border care is not a state program
Some U.S. residents travel outside the country for ibogaine-related services. That pattern can appear in investigations, consumer accounts, or safety discussions, but it does not establish legal access, clinical oversight, or an outcome expectation within a U.S. state.
Foreign clinic accounts
Reports about care outside the United States may inform an inquiry, but their details are not interchangeable with a verified U.S. program. For individual narratives, consult an ibogaine trip report archive as personal reporting rather than legal or clinical proof.
Claims need separation
Travel pages and outcome claims should be read apart from policy status. The long-term side-effect context is relevant when evaluating whether a description minimizes uncertainty or possible risk.
Place is not permission
A directory can describe locations without answering whether a practice is lawful or regulated. Use an ibogaine treatment location guide as a starting point for questions, not as confirmation of authorization.
Questions in view
Policy tracker FAQ
These distinctions help keep a state-by-state record factual, narrow, and useful for patients, families, advocates, researchers, and policymakers.
Does a state research proposal make ibogaine treatment legal there?
No. A proposal, appropriation, or study authorization must be read for its exact scope. It does not by itself change controlled-substance status or create a general treatment pathway. The PTSD treatment evidence context can help separate a condition-specific claim from the legal question.
How should enforcement actions against underground clinics be interpreted?
Start with the primary document and identify the agency, alleged conduct, cited authority, and case stage. Foreign clinic data may be part of an investigation, but the record should show that connection rather than assume it.
Can reported outcomes establish a policy or clinical conclusion?
No. Personal accounts and success-rate claims can be incomplete, selected, or difficult to verify. The ibogaine success-rate discussion belongs in an evidence-quality conversation, not as proof of a state policy outcome.
Why include cross-border treatment patterns at all?
They can clarify why a state inquiry, consumer warning, or advocacy claim refers to another country. For example, descriptions of Costa Rica ibogaine clinics may add travel context, but do not establish U.S. licensure, approval, or lawful access.
Evidence-first tracking
Use state records for what they say—and no more.
For the site’s scope, methods, and independence commitments, see how Open Field 30 approaches evidence and policy. This map is an independent information resource and should not be used as medical or legal advice.
View federal tracker